



Date: 14 February 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Stock Code: 542248

Subject: Outcome of the Board Meeting held on today i.e. 14 February 2025 and Submission of Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 31 December 2024

Dear Sir/Madam,

With reference to our Intimation vide letter dated Saturday, 10 February 2025 we wish to inform you that the Board Directors of the Company in its meeting held today i.e. Friday, 14 February 2025 through Video Conferencing/OAVM have Inter-alia;

1. Considered and Approved the Standalone Unaudited Financial Results of the Company for the quarter ended 31 December 2024 along with the Limited Review Report.
2. Considered and Approved the Consolidated Unaudited Financial Results of the Company for the quarter ended on 31 December 2024 along with the Limited Review Report.
3. Conversion of warrants into equity shares of the Company

With reference to our intimation dated 12 October 2023 and 10 February 2025, this is to inform you that our existing Warrant Holders (Promoter and Person Other than the Promoter and Promoter Group) has exercised their right for conversion of warrants into equity shares. Pursuant to the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Warrant Holders had paid 25% (Rs. 7.5/- per warrant) of the issue price of the warrant as the warrant subscription price. The balance 75% (Rs.22.5/- per warrant) of the issue price of warrants was to be paid at the time of exercise of option to apply for fully paid - up Equity shares of Re. 10/- each of the Company, against each such warrants held by the warrant holder.

In view of above and upon receipt from the warrant holders

- (a) **Shri Minto Gupta (Promoter and Promoter Group)** - the written notice and balance 75% (at the rate of Rs. 22.5/- per warrant) for 4,26,666 warrants for aggregating to Rs. 95,99,985/-, the Board of Directors of the Company at their meeting held on today i.e 14 February 2025 has allotted 4,26,666 equity shares of face value of Rs. 10/- each (Premium of Rs. 20/- per equity share) pursuant to exercise of 4,26,666 convertible warrants.

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427



Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



(b) M/s Krishna Ventures (Person Other than the Promoter and Promoter Group) - the written notice and balance 75% (at the rate of Rs. 22.5/- per warrant) for 3,33,000 warrants for aggregating to Rs. 74,92,500/-, the Board of Directors of the Company at their meeting held on today i.e 14 February 2025 has allotted 3,33,000 equity shares of face value of Rs. 10/- each (Premium of Rs. 20/- per equity share) pursuant to exercise of 3,33,000 convertible warrants.

Consequent to this conversion of warrants/allotment of Equity Shares 23,23,667 warrants remain pending for conversion and these warrant holders are entitled to get their warrants converted into Equity Shares of the Company by paying remaining 75% i.e., Rs. 22.5/- per warrant within 18 months from the date of warrant allotment. A list of allottees along with name of warrant holders whose warrants are pending for conversion is enclosed as **Annexure-I**.

Pursuant to present conversion, the Issued, Subscribed and Paid-up Equity Share Capital of the Company stands increased to Rs. 23,42,55,130 /- consisting of 2,34,25,513 fully paid-up Equity Shares of Rs. 10/-each from Rs. 22,66,58,470 /- consisting of 2,26,65,847 fully paid-up Equity Shares of Rs. 10/-each.

The new equity shares so allotted, shall rank pari-passu with the existing equity shares of the Company.

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July, 2023 is enclosed as **Annexure II** to this letter.

3. "Resignation of Shri Ramesh Kumar, Non- Executive Independent Director of the Company"

The Company has considered and approved the Resignation of Shri Ramesh Kumar, Non-Executive Independent Director of the Company w.e.f 31st December 2024 (close of business hours). Resignation Letter received from Shri Ramesh Kumar is enclosed as per **Annexure III**.

The Board Meeting commenced at 03:00 PM and concluded at 04:05 PM

You are requested to take the information on record.

Further the said outcome shall be uploaded on the website of the company at www.deccanhealthcare.co.in.

We request you to take the same on records.

Thanking You,

For and on behalf of

Deccan Health Care Limited

Minto Gupta
Chairman & Managing Director

Encl: a/a

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427



Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in


THE NAMES OF THE ALLOTTEES OF EQUITY SHARES PURSUANT TO CONVERSION OF WARRANTS ALLOTTED ON PREFERENTIAL BASIS:

S. No.	Name of Allotees	Warrants pending before conversion	No. of warrants applied for conversion	No of equity shares allotted	Amount received being 75% of the issue price per warrant (in Rs.)	Warrants pending after conversion
Promoter and Promoter Group Category (A)						
1.	Dr. Minto Purshotam Gupta	4,26,666	4,26,666	4,26,666	95,99,985	-
Total (A)		4,26,666	4,26,666	4,26,666	95,99,985	-
Public Category (B)						
1.	M/s Focal Ventures Private Limited	12,08,667	0	0	0	12,08,667
2.	M/s Krishna Ventures	4,48,000	3,33,000	3,33,000	74,92,500	1,15,000
3.	Mr. Akhil Bhandari	10,00,000	0	0	0	10,00,000
Total (B)		26,56,667	3,33,000	3,33,000	74,92,500	23,23,667
Total (A+B)		30,83,333	7,59,666	7,59,666	1,70,92,485	23,23,667



THE DETAILS AS REQUIRED UNDER REGULATION 30 OF SEBI LISTING REGULATIONS READ WITH SEBI CIRCULAR SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED 13 JULY, 2023

S. No.	Particulars	Details						
1	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity Shares pursuant to Conversion of Warrants						
2	Type of issuance	Preferential allotment						
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Total Number of Securities Allotted – 7,59,666 Equity Shares of Rs. 10/- each						
Additional Information in Case of Preferential Issue:								
4	Names of the investors;	Shri Minto Purshotam Gupta and M/s Krishna Ventures						
5	Post allotment of securities- Outcome of the subscription, Issue Price/Allotted Price (In case of Convertibles), Number of investors	<table border="1"> <thead> <tr> <th>Name of the Investor</th> <th>No. of Equity Shares Allotted</th> </tr> </thead> <tbody> <tr> <td>Shri Minto Purshotam Gupta</td> <td>4,26,666</td> </tr> <tr> <td>M/s Krishna Ventures</td> <td>3,33,000</td> </tr> </tbody> </table>	Name of the Investor	No. of Equity Shares Allotted	Shri Minto Purshotam Gupta	4,26,666	M/s Krishna Ventures	3,33,000
		Name of the Investor	No. of Equity Shares Allotted					
Shri Minto Purshotam Gupta	4,26,666							
M/s Krishna Ventures	3,33,000							
<p>Pursuant to present conversion, the Issued, Subscribed and Paid-up Equity Share Capital of the Company stands increased to Rs. 23,42,55,130 /- consisting of 2,34,25,513 fully paid-up Equity Shares of Rs. 10/-each from Rs 22,66,58,470 /- consisting of 2,26,65,847 fully paid-up Equity Shares of Rs. 10/-each</p> <p>30/- Per Equity Share</p> <p>Convertible Warrants under Preferential Issue were allotted to 4 Allottees on 12 October, 2023. Out of 4 Allottees, 2 Allottees, Shri Minto Purshotam Gupta and M/s Krishna Venture has exercised the right for conversion of warrants held into Equity Shares.</p>								



Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CTN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



Deccan
Healthcare
Limited

StayWoW

6	In case of convertibles – Intimation on onversion of securities or on lapse of the tenure of the instrument;	<p>Each Warrant held by the Allottees (“Warrant Holders”) shall entitle them to apply for and obtain allotment of one Equity Share for every one Warrant at any time in one or more tranches, within Eighteen (18) months from the date of allotment of warrants (the “Warrant Exercise Period”).</p> <p>An amount equivalent to 25% of the Warrant Issue Price has been received at the time of subscription and allotment of each Warrant and the balance 75% of the Warrant Issue Price shall be payable by the Warrant Holders at the time of submitting application for conversion of warrants for allotment of the equity shares pursuant to exercise of option attached to such Warrants.;</p> <p>In the event the Warrant Holder(s) do not exercise of option attached to such Warrants within the Warrant Exercise Period, the Warrants shall lapse and the amount paid shall stand forfeited by the Company.</p>
---	--	--




Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in

31st December, 2024

To,
The Chairman
Deccan Health Care Limited
H.No. 6-3-347/17/5/A/Back Position,
Dwarkapuri Colony,
Punjagutta Hyderabad TG 500082 IN

Sub: Resignation from the Independent Directorship of DHCL


Dear Sir,


Due to personal reasons, I will not be able to continue as Independent Director in Deccan Health Care Limited and hence hereby tendering my resignation with immediate effect.

I hereby confirm that there is no other material reason other than as mentioned above for my stepping down from the position of Independent Director of the Company

Request you to intimate/ notify my resignation to the Board of Directors, Registrar of Companies and Stock Exchange(s) and provide me with the copies of the same.

With Warm Regards,


Ramesh Kumar
DIN: 10480812


Ramesh Kumar
31/12/24



Date: 14 February 2025

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Stock Code: 542248

Subject: Submission of Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on 31 December 2024 along with Limited Review Reports issued by Statutory Auditors

Dear Sir/Madam

With reference to above captioned subject and pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 31 December 2024 along with the Limited Review Report issued by Statutory Auditors.

The said Financial Results were duly reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

We request you to take the same on records.

Thanking You,
Yours Faithfully,
For and on behalf of

Deccan Health Care Limited

Minto Gupta

Chairman & Managing Director

Encl: a/a



Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in



Independent Auditor's Limited Review Report on the Quarter and Nine Months Unaudited Financial Results of the Deccan Health Care Limited, for the Quarter and Nine Months ended 31st December, 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results of **Deccan Health Care Limited** for the Quarter and Nine Months ended **31st December, 2024** attached herewith, being submitted by the company pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement, which is the responsibility of the Company Management and approved by the Company Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquire of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we have not performed an audit and accordingly, we do not express an audit opinion.




Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Indian Accounting standard ("Ind AS") and other recognized accounting practices and policies as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Associates

Chartered Accountants

F.R.No. 333288W



Akhlaq Ahmad Mutvalli


Partner

Membership Number:-181329

UDIN: -25181329BMHBQN8678

Date:-14th February, 2025

Place:-Ahmedabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Standalone financial Results for the Quarter And Nine Months Ended on 31st December, 2024

Amounts in Lakhs (unless otherwise stated)

Sr. No.	Particulars	Quarter Ended		Nine Month Ended		Year Ended	
		31st Dec. 2024	30th Sept. 2024	31st Dec. 2023	31st Dec. 2024	31st Dec. 2023	31st March, 2024
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	Income From Operations						
	a) Revenue from Operations	2,042.88	1,882.08	1,534.31	5,431.07	4,376.07	5,972.89
	b) Other Income	-	0.11	0.03	0.11	0.66	1.37
	Total Income	2,042.88	1,882.19	1,534.34	5,431.18	4,376.73	5,974.26
II	Expenses						
	a) Cost of Materials Consumed	1,209.62	1,075.11	1,142.42	2,914.51	2,037.35	3,046.46
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	126.45	61.35	30.34	433.09	716.32	701.52
	c) Employee Benefit Expense	102.31	130.06	87.42	323.21	242.13	341.27
	d) Finance Costs	1.73	2.51	1.52	5.89	3.96	6.35
	e) Depreciation and Amortisation Expense	36.63	36.66	39.95	109.31	110.93	146.65
	f) Other Expenses	545.07	504.66	150.59	1,502.97	1,071.33	1,507.72
	Total Expenses	2,021.81	1,810.35	1,452.24	5,288.98	4,182.02	5,749.97
III	Profit/ (Loss) Before Tax (I-II)	21.07	71.84	82.10	142.20	194.71	224.29
IV	Tax Expense						
	a) Current Tax	9.08	21.62	32.16	46.57	66.41	85.60
	b) Deferred Tax (Asset)/Liabilities	(3.58)	(3.51)	(5.13)	(10.56)	(11.03)	(13.48)
	Total Tax Expense	5.50	18.11	27.03	36.01	55.38	72.12
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	15.57	53.73	55.07	106.19	139.33	152.17
VI	Other Comprehensive Income/ (Loss)						
	a) Items that will not be reclassified to Profit & Loss	(0.03)	(0.04)	(2.10)	(0.08)	(6.32)	(0.11)
	Income tax in respect of above	0.01	0.01	0.52	0.02	1.59	0.03
	b) Items that may be reclassified to Profit & Loss	-	-	-	-	-	-
	Income tax in respect of above	-	-	-	-	-	-
	Total Other Comprehensive Income/ (Loss)	(0.02)	(0.03)	(1.58)	(0.06)	(4.73)	(0.08)
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)	15.55	53.70	53.49	106.13	134.60	152.09
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,266.58	2,098.05	2,037.62	2,266.58	2,037.62	2,037.62
IX	Other Equity						7,666.03
X	Earnings Per Equity Share- Basic/Diluted						
	Basic	0.07	0.26	0.31	0.51	0.77	0.82
	Diluted (After conversion of warrants)	0.06	0.21	0.31	0.41	0.77	0.82

For, Deccan Health Care Limited


Minto P Gupta
Managing Director
(DIN: 00843784)



Date : 14th February, 2025
Place : Hyderabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Notes to Accounts -Standalone Financial Statement

[1] The above standalone financial results for the quarter ended 31st December, 2024 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th February, 2025. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as amended] prescribed under section 133 of the companies act, 2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] During the December quarter, the Company received Rs. 379.20 Lakhs from the warrant holders against which they have been allotted 16,85,334 equity shares .

[6] Out of Rs 379.20 lakhs Received from the warrant holders, Rs.192.00 lakhs has been utilized in accordance with the approved objectives associated with the conversion of the warrants.The remaining amount of Rs. 187.20 lakhs is pending to be utilised.

[7] The Status of investor's complaints during the quarter ended on 31st December 2024 as under:-

Complaints pending at the beginning of the period	Nil
Complaints received during the period	Nil
Complaints disposed during the period	Nil
Complaints resolved at the end of the period	Nil

For, Deccan Health Care Limited



Minto P Gupta
Managing Director
(DIN: 00843784)

Date : 14th February, 2025
Place : Hyderabad



Independent Auditor's Limited Review Report on unaudited Consolidated Financial Results of the Deccan Health Care Limited, for the Quarter and Nine months ended 31st December, 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors of,
Deccan Health Care Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Deccan Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter and Nine months ended **31st December, 2024** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Beyoungstore Private Limited ("Subsidiary")




Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the statement provided by the Management related to subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The accompanying Statement includes the unaudited interim financial results/ financial information in respect of:

We did not review the interim financial statements / financial information / financial results of subsidiary i.e. Beyoungstore Private Limited ("subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total income of Rs. 1.53 Lakhs , and total net profit/(loss) after tax of Rs. (1.14) lakhs, for the Quarter ended 31st December, 2024, as considered in the consolidated unaudited financial results, whose interim financial statements / financial information/ financial results have been reviewed by us. These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.

Our conclusion on the consolidated unaudited statement is not modified in respect of the above matters.

For Keyur Shah & Associates
Chartered Accountants
FRN/333288W



Akhlaq Ahmad Mutvalli
Partner

Membership Number:-181329
UDIN: - 25181329BMHBQ09114



Date:-14th February, 2025
Place:-Ahmedabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, Somajiguda, Hyderabad, Telangana - 500082

Consolidated financial Results for the Quarter And Nine Months Ended on 31st December 2024

Amounts in Lakhs (unless otherwise stated)


Sr. No.	Particulars	Amounts in Lakhs (unless otherwise stated)					
		Quarter Ended		Nine Months Ended		Year Ended	
		31st Dec. 2024	30th Sept. 2024	31st Dec. 2023	31st Dec. 2024	31st Dec. 2023	31st March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income From Operations						
	a) Revenue from Operations	2,042.88	1,882.08	1,534.31	5,431.07	4,376.07	5,972.89
	b) Other Income	-	0.11	0.03	0.11	0.72	1.47
	Total Income	2,042.88	1,882.19	1,534.34	5,431.18	4,376.79	5,974.36
II	Expenses						
	a) Cost of Materials Consumed	1,209.62	1,075.11	1,142.42	2,914.51	2,037.35	3,046.46
	b) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	126.45	61.35	30.34	433.09	716.32	701.52
	c) Employee Benefit Expense	104.63	132.39	90.19	330.30	250.86	352.38
	d) Finance Costs	1.74	2.52	3.64	5.91	6.09	8.50
	e) Depreciation and Amortisation Expense	36.63	36.66	39.95	109.31	110.93	146.65
	f) Other Expenses	543.88	503.20	149.22	1,498.53	1,064.39	1,497.47
	Total Expenses	2,022.95	1,811.23	1,455.76	5,291.65	4,185.94	5,752.98
III	Profit/ (Loss) Before Tax (I-II)	19.93	70.96	78.58	139.53	190.85	221.38
IV	Tax Expense						
	a) Current Tax	9.08	21.62	31.19	46.57	65.44	85.60
	b) Deferred Tax (Asset)/Liabilities	(3.58)	(3.51)	(5.13)	(10.56)	(11.03)	(13.48)
	Total Tax Expense	5.50	18.11	26.06	36.01	54.41	72.12
V	Net Profit/ (Loss) After Tax for the Period (III-IV)	14.43	52.85	52.52	103.52	136.44	149.26
VI	Other Comprehensive Income/ (Loss)						
	a) Items that will not be reclassified to Profit & Loss	(0.03)	(0.04)	(3.16)	(0.08)	(6.32)	(0.11)
	Income tax in respect of above	0.01	0.01	1.59	0.02	1.59	0.03
	b) Items that may be reclassified to Profit & Loss						
	Income tax in respect of above						
	Total Other Comprehensive Income/ (Loss)	(0.02)	(0.03)	(1.57)	(0.06)	(4.73)	(0.08)
VII	Total Comprehensive Income/ (Loss) for the period (V + VI)	14.41	52.82	50.95	103.46	131.71	149.18
VIII	Paidup Equity Share Capital (Facevalue Rs 10 each)	2,266.58	2,098.05	2,037.62	2,266.58	2,037.62	2,037.62
IX	Other Equity						7,653.82
X	Earnings Per Equity Share- Basic/Diluted						
	Basic	0.07	0.26	0.29	0.49	0.76	0.80
	Diluted (After Conversion of warrants)	0.06	0.21	0.29	0.40	0.76	0.80

For, Deccan Health Care Limited


Minto P Gupta
Managing Director
(DIN: 00843784)

Date : 14th February, 2025

Place : Hyderabad



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

6-3-347/17/5/A/Back Position, Dwarkapuri Colony, SomaJiguda, Hyderabad, Telangana - 500082

Notes to Accounts -Consolidated Financial Statement

[1] The above consolidated financial results for the quarter ended 31st December 2024 have been prepared by the Company in accordance with regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the board of directors in their meeting held on 14th February, 2025. A limited review of the above results has been carried out by the statutory auditors of the company.

[2] Previous Year's /period's figures have been regrouped/rearranged/ restated/adjusted/rectified/recasted wherever considered necessary.

[3] Basis of Preparation of the Statement and Adoption of Indian Accounting Standards. The Company has adopted Indian Accounting Standard (IND AS) specified under companies (Indian) Accounting Standard Rules, 2015 [as ammended] precribed under section 133 of the companies act,2013.

[4] The Company is engaged in manufacturing of nutraceutical products. Considering the nature of Business and Financial Reporting of the Company, the Company is operating in only one Segment. Hence segment reporting is not applicable.

[5] During the December quarter, the Company received Rs. 379.20 Lakhs from the warrant holders against which they have been allotted 16,85,334 equity shares .

[6] Out of Rs 379.20 lakhs Received from the warrant holders, Rs.192.00 lakhs has been utilized in accordance with the approved objectives associated with the conversion of the warrants.The remaining amount of Rs. 187.20 lakhs is pending to be utilised.

[7] The Status of investor's complaints during the quarter ended on 31st December 2024 as under:-

Complaints pending at the beginning of the period	NIL
Complaints received during the period	NIL
Complaints disposed during the period	NIL
Complaints resolved at the end of the period	NIL

Date : 14th February, 2025

Place : Hyderabad

For, Deccan Health Care Limited

Minto P Gupta
Managing Director
(DIN: 00843784)

